Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MGNX 
MacroGenics Inc (MGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MGNX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.4
1 Year Target Price $3.4
| 2 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.2% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.70M USD | Price to earnings Ratio - | 1Y Target Price 3.4 |
Price to earnings Ratio - | 1Y Target Price 3.4 | ||
Volume (30-day avg) 9 | Beta 1.64 | 52 Weeks Range 0.99 - 5.10 | Updated Date 09/17/2025 |
52 Weeks Range 0.99 - 5.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.99% | Operating Margin (TTM) -165.27% |
Management Effectiveness
Return on Assets (TTM) -21.84% | Return on Equity (TTM) -69.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46326617 | Price to Sales(TTM) 0.58 |
Enterprise Value -46326617 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 63205703 | Shares Floating 52560599 |
Shares Outstanding 63205703 | Shares Floating 52560599 | ||
Percent Insiders 3.25 | Percent Institutions 80.41 |
Upturn AI SWOT
MacroGenics Inc
Company Overview
History and Background
MacroGenics, Inc. was founded in 2000. It's a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. Significant milestones include the development of its DART platform and the approval of MARGENZA.
Core Business Areas
- Oncology: Development and commercialization of antibody-based therapeutics for cancer treatment. This includes clinical development programs and commercialization of approved products like MARGENZA.
- Novel Platforms: Research and development of innovative antibody platforms, such as DART, Fc optimization, and ADCT platforms.
Leadership and Structure
The leadership team includes Scott Koenig, M.D., Ph.D., as President and CEO. The company has a typical organizational structure for a biopharmaceutical company, with departments focused on research, development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- MARGENZA (margetuximab-cmkb): MARGENZA is an Fc-optimized antibody targeting HER2-positive breast cancer. It competes with other HER2-targeted therapies like Herceptin (trastuzumab) from Roche/Genentech, Perjeta (pertuzumab) from Roche/Genentech, and Enhertu (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo/AstraZeneca. Market share data is difficult to pinpoint precisely but it is less than Herceptin, Perjeta, and Enhertu in the overall HER2 breast cancer market. Revenue data is available in the company's financials.
- Enoblituzumab: An investigational anti-B7-H3 antibody being developed for various solid tumors. It's currently in clinical trials. Competitors depend on the specific cancer type being targeted but include other companies developing B7-H3 targeted therapies, such as Xencor.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, stringent regulatory requirements, and intense competition. There's a growing focus on targeted therapies and immunotherapies.
Positioning
MacroGenics is a mid-sized player focused on antibody-based therapeutics, particularly in oncology. Its competitive advantages include its proprietary DART platform and Fc optimization technology.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is substantial, reaching hundreds of billions of dollars. MacroGenics targets specific segments within oncology, such as HER2-positive breast cancer and tumors expressing B7-H3. MacroGenics has a good position in the market, especially with continued product innovation and development.
Upturn SWOT Analysis
Strengths
- Proprietary DART platform
- Fc optimization technology
- Approved product (MARGENZA)
- Experienced management team
- Strong pipeline of antibody-based therapeutics
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Competition from larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Need for further funding
Opportunities
- Expansion of MARGENZA into new indications
- Successful development and commercialization of pipeline products
- Strategic partnerships and collaborations
- Acquisition of complementary technologies or assets
- Expansion into new geographic markets
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from existing and emerging therapies
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ROCHE.SW
- AZN
- MRK
- BMY
- LLY
Competitive Landscape
MacroGenics faces competition from larger pharmaceutical companies with greater resources and broader product portfolios. Its advantages lie in its innovative technology platforms and focus on specific oncology targets. The competitive landscape is very robust, with a large market share of the cancer treatment market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are driven by clinical trial progress, regulatory approvals, and commercial performance of MARGENZA.
Future Projections: Future growth is dependent on the success of its pipeline products, expansion of MARGENZA, and strategic partnerships. Analyst estimates would be needed for concrete projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for pipeline candidates, seeking regulatory approvals, and exploring strategic collaborations.
Summary
MacroGenics is a biopharmaceutical company with promising technology platforms and an approved product, but also faces financial risks and intense competition. MARGENZA's market presence and the advancement of its clinical pipeline are positive indicators. However, clinical trial outcomes and market competition pose significant challenges. MacroGenics needs to carefully manage its finances and strategically execute its development programs to achieve long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | CEO, President & Director Mr. Eric Blasius Risser | ||
Sector Healthcare | Industry Biotechnology | Full time employees 341 | Website https://www.macrogenics.com |
Full time employees 341 | Website https://www.macrogenics.com | ||
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.